Regulus Therapeutics (NASDAQ:RGLS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm currently has a $1.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 11.11% from the company’s current price.

According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “

A number of other research analysts have also weighed in on the company. Chardan Capital restated a “neutral” rating on shares of Regulus Therapeutics in a report on Tuesday, January 16th. Leerink Swann began coverage on Regulus Therapeutics in a report on Friday, January 5th. They issued an “outperform” rating and a $2.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $4.00 target price on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $2.50.

Regulus Therapeutics (NASDAQ RGLS) traded down $0.04 during mid-day trading on Wednesday, hitting $1.35. The stock had a trading volume of 473,400 shares, compared to its average volume of 777,993. Regulus Therapeutics has a 52 week low of $0.79 and a 52 week high of $2.30. The company has a quick ratio of 6.77, a current ratio of 6.77 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $140.34, a price-to-earnings ratio of -1.01 and a beta of 1.55.

Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.18). Regulus Therapeutics had a negative return on equity of 189.71% and a negative net margin of 107,606.96%. research analysts expect that Regulus Therapeutics will post -1.03 EPS for the current year.

A number of institutional investors have recently modified their holdings of RGLS. Quantitative Investment Management LLC purchased a new position in shares of Regulus Therapeutics in the second quarter valued at $103,000. GSA Capital Partners LLP purchased a new position in Regulus Therapeutics during the second quarter worth about $139,000. Royal Bank of Canada grew its position in Regulus Therapeutics by 12.1% during the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock worth $182,000 after buying an additional 19,934 shares in the last quarter. Victory Capital Management Inc. purchased a new position in Regulus Therapeutics during the third quarter worth about $347,000. Finally, Goldman Sachs Group Inc. grew its position in Regulus Therapeutics by 189.1% during the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock worth $363,000 after buying an additional 240,890 shares in the last quarter. Institutional investors and hedge funds own 59.39% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/regulus-therapeutics-rgls-upgraded-by-zacks-investment-research-to-buy/1821750.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get a free copy of the Zacks research report on Regulus Therapeutics (RGLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.